197 related articles for article (PubMed ID: 26603202)
1. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
Svarovskaia ES; Gane E; Dvory-Sobol H; Martin R; Doehle B; Hedskog C; Jacobson IM; Nelson DR; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
J Infect Dis; 2016 Apr; 213(8):1240-7. PubMed ID: 26603202
[TBL] [Abstract][Full Text] [Related]
2. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
[TBL] [Abstract][Full Text] [Related]
3. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
Donaldson EF; Harrington PR; O'Rear JJ; Naeger LK
Hepatology; 2015 Jan; 61(1):56-65. PubMed ID: 25123381
[TBL] [Abstract][Full Text] [Related]
4. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
5. Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
McPhee F; Hernandez D; Zhou N
Antivir Ther; 2017; 22(3):237-246. PubMed ID: 28008868
[TBL] [Abstract][Full Text] [Related]
6. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.
Hedskog C; Dvory-Sobol H; Gontcharova V; Martin R; Ouyang W; Han B; Gane EJ; Brainard D; Hyland RH; Miller MD; Mo H; Svarovskaia E
J Viral Hepat; 2015 Nov; 22(11):871-81. PubMed ID: 25784085
[TBL] [Abstract][Full Text] [Related]
8. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.
Gane EJ; Metivier S; Nahass R; Ryan M; Stedman CA; Svarovskaia ES; Mo H; Doehle B; Dvory-Sobol H; Hedskog C; Lin M; Brainard DM; Yang JC; McHutchison JG; Sulkowski M; Younes Z; Lawitz E
Hepatol Commun; 2017 Aug; 1(6):538-549. PubMed ID: 29404477
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
[TBL] [Abstract][Full Text] [Related]
10. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.
Svarovskaia ES; Dvory-Sobol H; Parkin N; Hebner C; Gontcharova V; Martin R; Ouyang W; Han B; Xu S; Ku K; Chiu S; Gane E; Jacobson IM; Nelson DR; Lawitz E; Wyles DL; Bekele N; Brainard D; Symonds WT; McHutchison JG; Miller MD; Mo H
Clin Infect Dis; 2014 Dec; 59(12):1666-74. PubMed ID: 25266287
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
Peres-da-Silva A; Brandão-Mello CE; Lampe E
Antivir Ther; 2017; 22(5):447-451. PubMed ID: 28085003
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
13. Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients.
Younas S; Sumrin A; Hussain N; Bilal M
J Appl Microbiol; 2022 Nov; 133(5):2826-2834. PubMed ID: 35916643
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
Ampuero J; Reddy KR; Romero-Gomez M
World J Gastroenterol; 2016 Jun; 22(22):5285-92. PubMed ID: 27298572
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
17. Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
Uchida Y; Nakamura S; Kouyama JI; Naiki K; Motoya D; Sugawara K; Inao M; Imai Y; Nakayama N; Tomiya T; Hedskog C; Brainard D; Mo H; Mochida S
Sci Rep; 2018 Jun; 8(1):8818. PubMed ID: 29892096
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
Leumi S; Guo M; Lu J; Wang Z; Gan T; Han L; Ngari J; Tong Y; Xiang X; Xie Q; Wang L; Zhong J
Antiviral Res; 2022 Jan; 197():105224. PubMed ID: 34864126
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
[TBL] [Abstract][Full Text] [Related]
20. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]